Rayca Precision provides a secure research environment (SRE) that enables healthcare organizations to share and analyze sensitive patient data without it leaving its original location. This platform uses machine learning pipelines for applications such as biomarker discovery, genotype-phenotype prediction, and treatment response modeling, facilitating secure data collaboration and advanced analytics in healthcare.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery and development is a costly and time-consuming process, often plagued by high attrition rates due to late-stage failures. Identifying promising therapeutic candidates for complex and previously undruggable targets remains a significant challenge. Traditional methods struggle to integrate and analyze the vast amounts of multi-omics data required for effective drug design and optimization.
Solution
Rayca Precision offers an AI-driven drug discovery suite that accelerates the identification and optimization of therapeutic candidates, particularly for hard-to-drug targets. The platform integrates multi-omics data, virtual screening technologies, and predictive modeling to design and screen thousands of therapeutic candidates, including small molecules, biologics, and advanced modalities like RNA-based drugs. Rayca's closed-loop process incorporates continuous feedback from screening, in vitro testing, and preclinical validation, which refines AI models and improves future drug designs. By unifying diverse data sources in a data lakehouse architecture, the platform facilitates seamless analysis and eliminates barriers to interdisciplinary research, ultimately reducing development costs and increasing the likelihood of successful IND filings.
Target Audience
Rayca Precision primarily targets pharmaceutical and biotechnology organizations seeking novel therapeutic candidates in oncology, immunotherapy, and rare diseases.
Features
- AI-driven design and optimization of small molecules, antibodies, peptides, proteins, and CAR proteins
- Multi-layered in silico filtering to assess hydrophobicity, hydrogen-bonding potential, and ADMET traits early in the design phase
- Computational protein design principles to pinpoint key epitopes and map potential immunogenic hotspots for biologics
- Integration of nucleotide-level structural insights with multi-omics signatures for iterative refinement of RNA sequences and delivery vehicles
- Data lakehouse architecture that merges genomic, proteomic, and transcriptomic profiles for unified analysis
- Predictive modeling to detect off-target toxicities and pharmacokinetic risks early in development
- Version-controlled computational steps benchmarked against experimental results for an auditable trail
- Platforms include RSA2™ for bioinformatics analysis and OncoCrest™ for precision oncology